current knowledge of the tp53 mutation and its role in cll
Published 5 years ago • 2.2K plays • Length 2:36Download video MP4
Download video MP3
Similar videos
-
1:38
the importance of tp53 in cll
-
1:26
the role of tp53 in cll
-
3:08
recent updates on tp53 mutation in cll
-
4:31
the impact of high and low burden tp53 mutations on risk and treatment decision in cll
-
2:14
the importance of tp53 testing in cll
-
10:30
leukemia patient story: my 1st symptoms for cll | stephen's story (1/5) | the patient story
-
8:14
progress in the treatment of tp53 mutated aml
-
5:03
ighv-mutated vs ighv-unmutated cll | what’s the difference?
-
3:13
tp53 mutations in cll: a large retrospective analysis
-
2:27
the importance of tp53 & ighv testing before treatment initiation in cll
-
2:02
the prognostic impact of tp53 and ighv status in the era of targeted therapies in cll
-
1:21
identifying low-burden tp53 mutations with ngs in cll
-
2:07
efficacy of ibrutinib in the treatment of cll patients with del(17p) and tp53 mutation
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
0:54
re-testing in cll: fish analysis and tp53 screening
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
-
5:16
an analysis of tp53 mutation in aml and hr-mds
-
14:54
assessing the role of car-t in cll
-
1:48
characterizing the development of mds in patients with cll in the era of targeted therapies
-
2:08
identifying tp53 disruptions: a diagnostic measure in cll
-
17:23
updates in cll: key clinical trials in the frontline and r/r setting, pre-clinical data and mrd
-
2:06
the role of ibrutinib in the frontline treatment of young patients with cll